Corporate News
Speculation regarding a potential fundraise
10 February 2022
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, notes today’s online speculation and confirms that it has conditional investor support for an equity fundraising at 5p per share and that it is considering undertaking a share placing to raise approximately £5m with an accompanying open offer to raise up to a further £2m.
Any such fundraising would however be conditional upon certain other corporate actions currently being explored by the Group and, accordingly, there is no certainty at this time that any such fundraise will proceed.
A further announcement will be made in due course as necessary.
Contacts:
www.omegadx.com
| Jag Grewal, Chief Executive Officer | via Walbrook PR |
| Chris Lea, Chief Financial Officer | |
| finnCap Ltd | Tel: 020 7220 0500 |
| Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance) | |
| Alice Lane/ Charlotte Sutcliffe (ECM) | |
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] |
| Paul McManus | Mob: 07980 541 893 |
| Lianne Applegarth | Mob: 07584 391 303 |
| Sam Allen | Mob: 07502 558 258 |
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.
